ALS: A Quick Breakthrough in Early Diagnosis — and Why It could Change Everything
ALS is a severe condition that destroys motor neurons, leading to progressive paralysis. It’s relatively rare, affecting about 1.6 in 100,000 adults, which translates to roughly 30,000 people with ALS in the United States at any given time. The tough part is diagnosing it early: many patients wait more than a year from first symptoms to an accurate diagnosis, and up to 68% are initially misdiagnosed. People often cycle through multiple specialists before a neurologist with ALS experience confirms the diagnosis.
A fresh rapid blood test from Brain Chemistry Labs in Jackson Hole, Wyoming, promises to change this. After analyzing 788 blood samples (393 from ALS patients and 395 from age- and gender-matched healthy controls), researchers report that the test can identify ALS with 97% accuracy from a single blood draw. Even better, it can help rule out ALS in those who don’t have the disease.
The test relies on microRNA, small genetic pieces that usually regulate protein production. This approach could enable diagnosis at the earliest possible stage, which is crucial for patient outcomes.
Most ALS cases are sporadic (about 90%), with only around 10% having a family history. Today, there are no commercially available tests to detect sporadic ALS early. Impressively, the new miRNA-based test shows equal accuracy for both sporadic and familial ALS.
“For ALS, which commonly leads to death within 2–5 years after symptoms appear, delaying diagnosis by a year is unacceptable,” says Dr. Rachael Dunlop, the paper’s first author in Molecular Neurobiology. “This test makes it possible for patients to start therapy earlier.”
Dr. Paul Alan Cox, Executive Director and co-founder of Brain Chemistry Labs, emphasizes the unmet needs of the ALS community. “The patient population is deeply underserved, so as a not-for-profit, we have relentlessly pursued this diagnostic advance.”
Brain Chemistry Labs is seeking a commercial partner to bring the test to market. At a recent International Symposium on ALS/MND in San Diego, Dr. Sandra Banack and Dr. Dunlop shared these findings and discussed next steps.
Origins of the approach trace back to ethnobotanical research on neurological diseases in small island communities. The lab combines these insights with modern neuroscience to pursue prevention, diagnosis, and treatment across neurodegenerative diseases, including Alzheimer’s and Parkinson’s, as well as ALS. Dr. Cox notes that while big pharma may favor Alzheimer’s and Parkinson’s, the team remains committed to ALS patients and challenges.
Related information and cautions:
- The content above comes from a journal report and press materials and should be interpreted in context.
- No medical advice is given here; consult a healthcare professional for medical guidance.
Would you like a brief explainer outlining how microRNA-based tests work, plus a sidebar on what this could mean for ALS care timelines? Also, would you prefer this rewritten in a more formal medical style or a more accessible, layperson-friendly tone?
